Abstract: Methods and compounds are disclosed for wound healing by modulating autophagy. A formulation for modulating autophagy comprises a first modulating compound (FAM) selected from compounds having the general structure (I): wherein: L represents a linker selected from —C?C—, (a tolan), —CH?CH— (a stilbene, preferably trans); or —CRa?CRb— a stilbene derivative; where Ra and Rb are independently H or phenyl optionally substituted with —(R3)p or —(R4)q; R1 to R4 are independent substituents at any available position of the phenyl rings, preferably at 3, 3?, 4, 4?, and/or 5, 5?; and m, n, p, and q are independently 0, 1, 2, or 3 representing the number of substituents of the rings, respectively, but at least one of m or n must be ?1. Each R1 to R2 is independently selected from substituents described herein, including but not limited to hydroxyl, alkoxy, halo, halomethyl and glycosides. The formulation may also include an auxiliary autophagy modulating compound (AAM) as described herein.

Abstract: A coupling agent composition is provided and includes a plurality of non-toxic components in an amount equal to or greater than 97 weight percent (wt %). The coupling agent composition includes a carrier of water, at least one water soluble polyol selected from the group consisting of propanediol, pentylene glycol, and butylene glycol, a thickening agent having a naturally derived soluble polymer additive selected from a group consisting of xanthan gum, carrageenan, guar, locust bean, sodium hyaluronate, sodium alginate, acacia, tara gum, tamarind seed, succinoglycan, scleroglucan, and mannan, and a balance of incidental impurities.

Abstract: Disclosed a method of preparing composite particles comprising a non-porous spherical particulate inorganic material deposited on a plate-like inorganic material, where refractive index of said particulate inorganic material is greater than that of said plate-like inorganic particulate material, wherein, said spherical material occupies 20 to 80% of total surface area of said plate-like material and wherein the amount of said spherical material accounts for 2 to 20 wt % of said composite particles, further wherein said plate-like inorganic material is mica and said non-porous spherical particulate inorganic material is silicone dioxide, said method comprising the steps of: (iv) silanization of said plate-like inorganic material to get a silanized material having functional groups “A”; (v) silanization of said non-porous spherical particulate inorganic material to get a silanized material having functional groups “B”, where A?B; and where said “A” and said “B” are capable of reacting with each other such that

Abstract: Described herein are methods for treating T-cell lymphoma in a subject in need thereof, comprising administering to the subject in need thereof, an ETP compound. Also described herein are pharmaceutical compositions and compositions for use that include such ETP compound.

Abstract: The invention provides antibiotic combination therapies for treating an A. baumannii infection in a subject. The combination therapies include rifabutin and a second antibiotic, such as colistin and cefiderocol.

Abstract: The subject invention provides materials and methods for improving facial skin, hair and scalp health using cosmetic yeast-based masks. In a specific embodiment, the subject invention provides a yeast-based mask for application to the face, which can improve the health and appearance of thereof. In another specific embodiment, the subject invention provides a yeast-based mask for application to the hair and scalp, which can aid in preventing hair loss, as well as improve the health and appearance of the hair and scalp. Methods of using the yeast-based masks are also provided.

Abstract: A composition comprising: at least one compound of the chemical structure: ? H x ? O ( x - 1 ) 2 ? ? Z y wherein x is and odd integer ?3; y is an integer between 1 and 20; and Z is one of a monoatomic ion from Groups 14 through 17 having a charge value between ?1 and ?3 or a polyatomic ion having a charge between ?1 and ?3; or Z?—Hx?Ox??y? wherein x? is and integer greater than 3 y? is an integer less than x?; and Z? is one of a monoatomic cation, a polyatomic ion or a cationic complex; and at least one of a humectant emollient or carrier.

Abstract: The present invention relates to high-efficiency encapsulation of hydrophilic substances in the hydrophilic space of unilamellar liposomes. High-efficiency encapsulation is achieved by the use of a polyhydric alcohol selected from propylene glycol or glycerine for dissolving the hydrophobic compounds forming the lipid bilayer of the liposomes. The invention provides unilamellar liposomes (UL) as well as a method for preparing same by way of low temperature extrusion. The invention also relates to use of these UL in the manufacturing of a medicament, a cosmetic product, a food additive or a disinfectant.

Abstract: Provided is a curable composition that has a sufficient pot life and does not cause a significant delay in curing time even after long-term storage at room temperature or higher. A separately packed curable composition includes: (A) a first pack containing: (a1) a polymerizable monomer having no acidic group, (b) a polymerizable monomer having an acidic group, and (c) a transition metal compound; and (B) a second pack containing: (a2) a polymerizable monomer having no acidic group, (d) an aromatic amine compound, and (e) at least one compound selected from sulfinic acid and a salt thereof.

Abstract: Disclosed are methods of preparing thiol keratin-containing materials, comprising applying a mixture comprising one or more thiol compounds and a catalyst. Methods of preparing cross-linked keratin-containing materials by applying a mixture comprising one or more thiol compounds and an oxidizing agent are also disclosed. Methods of grafting monomeric and polymeric materials on keratin-containing materials to provide a covalent coating on keratin-containing materials are disclosed. A mixture comprising one or more thiol compounds is applied to the keratin-containing material sample. The keratin-containing material sample then comprises a plurality of free thiol groups. A monomer is optionally applied to the keratin-containing material sample to form a plurality of covalent bonds between the free thiol groups and the monomers. The disclosed grafting methods can be carried out with or without catalyst.

Abstract: The present invention provides a simple and improved dosage form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.

Abstract: The disclosure relates generally to polyglutamated antifolates, formulations containing liposomes filled with the polyglutamated antifolates, methods of making the polyglutamated antifolates and liposome containing formulations, and methods of using the polyglutamated antifolates and liposome containing formulations to treat hyerproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).

Abstract: Disclosed are hair care and hair cleansing compositions as well as skin care and skin cleansing compositions comprising a fibrous material of natural origin and obtained from plants. The fibrous material comprises micro-scaled and/or nano-scaled fibril agglomerates. Such compositions show pleasant skin feel and comfort during and after application, as well as fast drying and fast absorption into skin. The compositions obtained are also particularly well suited for the topical delivery of cosmetic and pharmaceutical active substances into skin. Additionally, a method to obtain said hair care or hair cleansing composition or said skin care or skin cleansing composition is disclosed.

Abstract: The present invention is related to compositions containing extracellular vesicles (exosomes) and methods of using the same for increasing lifespan of fetus, viability of fetus, or viability of newborn, for treating inflammation in uterus and/or fetus, for delaying preterm birth, or for treating a condition related to inflammation in uterus and/or fetus, wherein the extracellular vesicles comprising a nuclear factor kappa beta (NF-?B) inhibitor and a photo-specific binding protein.

Abstract: A pain relief device and method or system to aid in the resolution of pain in a body including at least one layer of PVDF film and at least one other layer for directional purposes, as well as a polarizing layer. The device can be packaged in various ways. Also described is a device that uses a combination of LED bulbs, polymer based materials and a near field accelerator to provide pain relief.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: The present invention provides a simple and improved dose form that is capable of providing a controlled release of GABAB receptor agonist contained in the core thereof. The invention also provides methods of administering the dosage form and of treating conditions that are therapeutically responsive to GABAB receptor agonist.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: A conjunctival cover including an annular generally curved shell having a conjunctival portion structured to conform to and overly at least part of the conjunctiva of an eye. The annular generally partially spherical shell defines a generally central opening. The central opening is sized to leave a cornea of the eye substantially or partially uncovered when the conjunctival cover is applied to the eye.